X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Indoco Remedies with REDINGTON (INDIA) - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs REDINGTON (INDIA) - Comparison Results

INDOCO REMEDIES    Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

REDINGTON (INDIA) 
   Change

Redington India, incorporated in 1961, commenced the operations in 1993 distributing information technology (IT) products. Now the company along with its subsidiaries is in the business of end-to-end supply chain management of IT and non- IT products... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES REDINGTON (INDIA) INDOCO REMEDIES/
REDINGTON (INDIA)
 
P/E (TTM) x 23.1 15.1 152.2% View Chart
P/BV x 2.7 2.5 109.6% View Chart
Dividend Yield % 0.8 1.3 64.5%  

Financials

 INDOCO REMEDIES   REDINGTON (INDIA)
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-17
REDINGTON (INDIA)
Mar-15
INDOCO REMEDIES/
REDINGTON (INDIA)
5-Yr Chart
Click to enlarge
High Rs360136 264.4%   
Low Rs249120 207.9%   
Sales per share (Unadj.) Rs119.0789.5 15.1%  
Earnings per share (Unadj.) Rs8.49.7 86.5%  
Cash flow per share (Unadj.) Rs15.210.7 141.9%  
Dividends per share (Unadj.) Rs1.601.90 84.2%  
Dividend yield (eoy) %0.51.5 35.4%  
Book value per share (Unadj.) Rs70.759.4 119.0%  
Shares outstanding (eoy) m92.15399.70 23.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.60.2 1,578.6%   
Avg P/E ratio x36.413.2 275.2%  
P/CF ratio (eoy) x20.011.9 167.8%  
Price / Book Value ratio x4.32.2 199.9%  
Dividend payout %19.119.6 97.4%   
Avg Mkt Cap Rs m28,08351,182 54.9%   
No. of employees `0006.0NA-   
Total wages/salary Rs m2,1674,677 46.3%   
Avg. sales/employee Rs Th1,817.0NM-  
Avg. wages/employee Rs Th359.0NM-  
Avg. net profit/employee Rs Th127.7NM-  
INCOME DATA
Net Sales Rs m10,968315,549 3.5%  
Other income Rs m40678 5.9%   
Total revenues Rs m11,007316,227 3.5%   
Gross profit Rs m1,5656,940 22.5%  
Depreciation Rs m633426 148.6%   
Interest Rs m621,586 3.9%   
Profit before tax Rs m9095,606 16.2%   
Minority Interest Rs m0-238 0.0%   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m0-52 0.0%   
Tax Rs m1391,450 9.6%   
Profit after tax Rs m7713,865 19.9%  
Gross profit margin %14.32.2 648.7%  
Effective tax rate %15.325.9 58.9%   
Net profit margin %7.01.2 573.7%  
BALANCE SHEET DATA
Current assets Rs m5,72580,200 7.1%   
Current liabilities Rs m5,45456,447 9.7%   
Net working cap to sales %2.57.5 32.8%  
Current ratio x1.01.4 73.9%  
Inventory Days Days6233 188.4%  
Debtors Days Days7251 140.4%  
Net fixed assets Rs m5,3072,152 246.7%   
Share capital Rs m184799 23.1%   
"Free" reserves Rs m6,33120,810 30.4%   
Net worth Rs m6,51623,742 27.4%   
Long term debt Rs m1,3231,011 130.9%   
Total assets Rs m11,97083,829 14.3%  
Interest coverage x15.64.5 345.0%   
Debt to equity ratio x0.20 477.1%  
Sales to assets ratio x0.93.8 24.3%   
Return on assets %7.06.5 107.0%  
Return on equity %11.816.3 72.7%  
Return on capital %12.427.9 44.4%  
Exports to sales %00 0.0%   
Imports to sales %04.0 0.0%   
Exports (fob) Rs mNA106 0.0%   
Imports (cif) Rs mNA12,758 0.0%   
Fx inflow Rs m4,507863 522.5%   
Fx outflow Rs m1,14113,108 8.7%   
Net fx Rs m3,366-12,245 -27.5%   
CASH FLOW
From Operations Rs m8862,568 34.5%  
From Investments Rs m-1,706-55 3,078.5%  
From Financial Activity Rs m1,316-2,249 -58.5%  
Net Cashflow Rs m497264 187.8%  

Share Holding

Indian Promoters % 59.2 0.0 -  
Foreign collaborators % 0.0 21.0 -  
Indian inst/Mut Fund % 12.5 7.5 166.7%  
FIIs % 6.0 37.3 16.1%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 34.1 65.7%  
Shareholders   12,805 14,740 86.9%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   EDELWEISS FINANCIAL  REPCO HOME  MIC ELECTRONICS  TATA INVEST. CORP.  KITEX GARMENTS  



Today's Market

Weak Finish to the Week Post Vishal Sikka's Exit as CEO of Infosys(Closing)

Share markets in India witnessed selling pressure, led by slump in shares of Infosys Ltd. after Vishal Sikka resigned as chief executive officer of the country's second-largest software services exporter.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Aug 18, 2017 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 8-QTR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS